A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
您可能感興趣的試卷
你可能感興趣的試題
A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
A.血紅蛋白測定
B.血清鐵蛋白測定
C.紅細(xì)胞游離原卟啉測定
D.血清鐵測定
E.血清總鐵結(jié)合力
A.血紅蛋白測定
B.血清鐵蛋白測定
C.紅細(xì)胞游離原卟啉測定
D.血清鐵測定
E.血清總鐵結(jié)合力
最新試題
目前非霍奇金淋巴瘤的治療主要是()
小兒惡性淋巴瘤骨髓受累,伴淋巴結(jié)腫大屬于哪一臨床分期()
診斷慢性ITP的主要根據(jù)為有ITP表現(xiàn)且病程超過()
大劑量甲氨蝶呤應(yīng)用于兒童急性淋巴細(xì)胞白血病的主要目的是()
ITP的主要臨床特點(diǎn)是()
考慮組織細(xì)胞壞死性淋巴結(jié)炎診斷主要依據(jù)()
大劑量甲氨蝶呤靜脈注射后用哪種藥物解救治療()
對兒童急性淋巴細(xì)胞白血病長期無病生存影響最重要的藥物是()
免疫抑制劑治療感染相關(guān)噬血細(xì)胞綜合征的主要原理是()
地中海貧血患者反復(fù)輸血的主要并發(fā)癥是()